|
 |
| home > epc > winter 2001 > the monoclonal anti-idiotype antibody aca 125 - a breakthrough for ovarian cancer |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Q About 1.5 per cent of the female population suffer from ovarian
carcinoma - a tumour disease with a high mortality rate - in the
course of their lifetime. It is the fourth most common cause of
death from cancer in women. So why is the prognosis of this
malignant disease so bad?
A Due to the difficulties in making an early diagnosis of ovarian carcinoma, more than 70 per cent of the patients are only diagnosed at advanced stages and almost 20 per cent are already at stage four by the time of diagnosis. Accordingly, the prognosis for these tumours is comparatively poor. Although the prognosis for all stages regarding five-year survival has meanwhile increased, the relative five-year survival rate with advanced tumours is essentially lower. The number of lost years of life adds up to a total of about 100,000 years within the Federal Republic of Germany alone.
Q What approach is taken to the therapy of ovarian carcinoma
depending on the severity, for example a favourable prognosis,
but also rapid progression of large tumour masses and visceral
metastases?
A The aim of primary treatment of ovarian carcinoma is to firstly attain a favourable starting position for further treatment. The prognosis of the disease heavily depends on the post-operative tumour remains from the initial surgical operation. Subsequent treatment by means of chemotherapy - which must be carried out after the operation - is clearly dependent on the result of the surgical operation. Response rates of between 70 and 80 per cent are attained here. However, a smaller number of patients progress relatively quickly into a relapse situation, even after optimal initial therapy that appears to be resistant to chemotherapy and incurable.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
2nd Annual Mobile Healthcare Industry Summit
21-22 September 2010, Radisson Blu Hotel, London
Informa present the 2nd Annual Mobile Healthcare Industry Summit! One year on and the launch event which brought global wireless healthcare innovation first in Europe is back…
More info >> |
|
 |
News and Press Releases |
 |
The highest performance in its class
Shimadzu, one of the worldwide leading manufacturers in analytical instrumentation, has launched a new GCMS-QP2010 Ultra gas chromatograph mass spectrometer (GC/MS) offering the highest performance in its class. It provides fast data measurement speed with five times higher sensitivity than previous models. In addition to improving laboratory productivity for high-speed analysis, it also offers improved applicability for comprehensive two-dimensional gas chromatography (GCxGC), which can achieve ultra high separation. It is also the first GC/MS system to have environmentally friendly features for saving power consumption and carrier gas.
More info >> |
|
 |
